Myelodysplastic Syndrome

News alerts, weekly reports and conference planners

IDH1 mutation	Myelodysplastic Syndrome	IDH1 mutation	Myelodysplastic Syndrome	ivosidenib Sensitive: C1 - Off-label EHA 2023 - 2 weeks (New C3) ivosidenib Sensitive : C1 EHA 2023 - 2wk	ivosidenib Sensitive: C1 - Off-label EHA 2023 - 2 weeks ivosidenib Sensitive : C1 EHA 2023 - 2 weeks - (New C3)
WT1 overexpression	Myelodysplastic Syndrome	WT1 overexpression	Myelodysplastic Syndrome	azacitidine Resistant: C3 – Early Trials EHA 2023 - 2 weeks (New C3) azacitidine Resistant : C3 EHA 2023 - 2wk	azacitidine Resistant: C3 – Early Trials EHA 2023 - 2 weeks azacitidine Resistant : C3 EHA 2023 - 2 weeks - (New C3)
Chr del(5q)	Myelodysplastic Syndrome	Chr del(5q)	Myelodysplastic Syndrome	VRD Sensitive: C4 – Case Studies EHA 2023 - 2 weeks (New C4) VRD Sensitive : C4 EHA 2023 - 2wk	VRD Sensitive: C4 – Case Studies EHA 2023 - 2 weeks VRD Sensitive : C4 EHA 2023 - 2 weeks - (New C4)
No biomarker	Myelodysplastic Syndrome	No biomarker	Myelodysplastic Syndrome	decitabine/cedazuridine Sensitive: A1 - Approval decitabine / cedazuridine Sensitive : A1	decitabine/cedazuridine Sensitive: A1 - Approval decitabine / cedazuridine Sensitive : A1
No biomarker	Myelodysplastic Syndrome	No biomarker	Myelodysplastic Syndrome	luspatercept-aamt Sensitive: A1 - Approval luspatercept-aamt Sensitive : A1	luspatercept-aamt Sensitive: A1 - Approval luspatercept-aamt Sensitive : A1
Chr del(5q)	Myelodysplastic Syndrome	Chr del(5q)	Myelodysplastic Syndrome	lenalidomide Sensitive: A1 - Approval lenalidomide Sensitive : A1	lenalidomide Sensitive: A1 - Approval lenalidomide Sensitive : A1
No biomarker	Myelodysplastic Syndrome	No biomarker	Myelodysplastic Syndrome	azacitidine Sensitive: A1 - Approval azacitidine Sensitive : A1	azacitidine Sensitive: A1 - Approval azacitidine Sensitive : A1
No biomarker	Myelodysplastic Syndrome	No biomarker	Myelodysplastic Syndrome	decitabine Sensitive: A1 - Approval decitabine Sensitive : A1	decitabine Sensitive: A1 - Approval decitabine Sensitive : A1
PDGFRA rearrangement	Myelodysplastic Syndrome	PDGFRA rearrangement	Myelodysplastic Syndrome	imatinib Sensitive: A1 - Approval imatinib Sensitive : A1	imatinib Sensitive: A1 - Approval imatinib Sensitive : A1
CALR mutation	Myelodysplastic Syndrome	CALR mutation	Myelodysplastic Syndrome	luspatercept-aamt Sensitive: A2 - Guideline luspatercept-aamt Sensitive : A2	luspatercept-aamt Sensitive: A2 - Guideline luspatercept-aamt Sensitive : A2
CALR mutation	Myelodysplastic Syndrome	CALR mutation	Myelodysplastic Syndrome	lenalidomide Sensitive: A2 - Guideline lenalidomide Sensitive : A2	lenalidomide Sensitive: A2 - Guideline lenalidomide Sensitive : A2
MPL W515L	Myelodysplastic Syndrome	MPL W515L	Myelodysplastic Syndrome	luspatercept-aamt Sensitive: A2 - Guideline luspatercept-aamt Sensitive : A2	luspatercept-aamt Sensitive: A2 - Guideline luspatercept-aamt Sensitive : A2
MPL W515L	Myelodysplastic Syndrome	MPL W515L	Myelodysplastic Syndrome	lenalidomide Sensitive: A2 - Guideline lenalidomide Sensitive : A2	lenalidomide Sensitive: A2 - Guideline lenalidomide Sensitive : A2
JAK2 V617F	Myelodysplastic Syndrome	JAK2 V617F	Myelodysplastic Syndrome	luspatercept-aamt Sensitive: A2 - Guideline luspatercept-aamt Sensitive : A2	luspatercept-aamt Sensitive: A2 - Guideline luspatercept-aamt Sensitive : A2
SF3B1 mutation	Myelodysplastic Syndrome	SF3B1 mutation	Myelodysplastic Syndrome	luspatercept-aamt Sensitive: A2 - Guideline luspatercept-aamt Sensitive : A2	luspatercept-aamt Sensitive: A2 - Guideline luspatercept-aamt Sensitive : A2
JAK2 V617F	Myelodysplastic Syndrome	JAK2 V617F	Myelodysplastic Syndrome	lenalidomide Sensitive: A2 - Guideline lenalidomide Sensitive : A2	lenalidomide Sensitive: A2 - Guideline lenalidomide Sensitive : A2
RUNX1 mutation	Myelodysplastic Syndrome	RUNX1 mutation	Myelodysplastic Syndrome	ruxolitinib Sensitive: A2 - Guideline ruxolitinib Sensitive : A2	ruxolitinib Sensitive: A2 - Guideline ruxolitinib Sensitive : A2
SETBP1 mutation	Myelodysplastic Syndrome	SETBP1 mutation	Myelodysplastic Syndrome	ruxolitinib Sensitive: A2 - Guideline ruxolitinib Sensitive : A2	ruxolitinib Sensitive: A2 - Guideline ruxolitinib Sensitive : A2
CBL mutation	Myelodysplastic Syndrome	CBL mutation	Myelodysplastic Syndrome	ruxolitinib Sensitive: A2 - Guideline ruxolitinib Sensitive : A2	ruxolitinib Sensitive: A2 - Guideline ruxolitinib Sensitive : A2
NRAS mutation	Myelodysplastic Syndrome	NRAS mutation	Myelodysplastic Syndrome	ruxolitinib Sensitive: A2 - Guideline ruxolitinib Sensitive : A2	ruxolitinib Sensitive: A2 - Guideline ruxolitinib Sensitive : A2
ASXL1 mutation	Myelodysplastic Syndrome	ASXL1 mutation	Myelodysplastic Syndrome	ruxolitinib Sensitive: A2 - Guideline ruxolitinib Sensitive : A2	ruxolitinib Sensitive: A2 - Guideline ruxolitinib Sensitive : A2
SRSF2 mutation	Myelodysplastic Syndrome	SRSF2 mutation	Myelodysplastic Syndrome	ruxolitinib Sensitive: A2 - Guideline ruxolitinib Sensitive : A2	ruxolitinib Sensitive: A2 - Guideline ruxolitinib Sensitive : A2
TET2 mutation	Myelodysplastic Syndrome	TET2 mutation	Myelodysplastic Syndrome	ruxolitinib Sensitive: A2 - Guideline ruxolitinib Sensitive : A2	ruxolitinib Sensitive: A2 - Guideline ruxolitinib Sensitive : A2
ETNK1 mutation	Myelodysplastic Syndrome	ETNK1 mutation	Myelodysplastic Syndrome	ruxolitinib Sensitive: A2 - Guideline ruxolitinib Sensitive : A2	ruxolitinib Sensitive: A2 - Guideline ruxolitinib Sensitive : A2
STAT3 mutation	Myelodysplastic Syndrome	STAT3 mutation	Myelodysplastic Syndrome	eltrombopag + cyclosporin A microemulsion Sensitive: A2 - Guideline eltrombopag + cyclosporin A microemulsion Sensitive : A2	eltrombopag + cyclosporin A microemulsion Sensitive: A2 - Guideline eltrombopag + cyclosporin A microemulsion Sensitive : A2
No biomarker	Myelodysplastic Syndrome	No biomarker	Myelodysplastic Syndrome	eltrombopag + cyclosporin A microemulsion Sensitive: A2 - Guideline eltrombopag + cyclosporin A microemulsion Sensitive : A2	eltrombopag + cyclosporin A microemulsion Sensitive: A2 - Guideline eltrombopag + cyclosporin A microemulsion Sensitive : A2
TP53 mutation	Myelodysplastic Syndrome	TP53 mutation	Myelodysplastic Syndrome	APR-246 Sensitive: B - Late Trials APR-246 Sensitive : B	APR-246 Sensitive: B - Late Trials APR-246 Sensitive : B
No biomarker	Myelodysplastic Syndrome	No biomarker	Myelodysplastic Syndrome	GS-4721 Sensitive: B - Late Trials GS-4721 Sensitive : B	GS-4721 Sensitive: B - Late Trials GS-4721 Sensitive : B
DNMT3A mutation + SF3B1 mutation	Myelodysplastic Syndrome	DNMT3A mutation + SF3B1 mutation	Myelodysplastic Syndrome	lenalidomide Resistant: B - Late Trials lenalidomide Resistant : B	lenalidomide Resistant: B - Late Trials lenalidomide Resistant : B
No biomarker	Myelodysplastic Syndrome	No biomarker	Myelodysplastic Syndrome	MLN4924 Sensitive: B - Late Trials MLN4924 Sensitive : B	MLN4924 Sensitive: B - Late Trials MLN4924 Sensitive : B
No biomarker	Myelodysplastic Syndrome	No biomarker	Myelodysplastic Syndrome	lenalidomide Sensitive: B - Late Trials lenalidomide Sensitive : B	lenalidomide Sensitive: B - Late Trials lenalidomide Sensitive : B
Chr del(5)(q31)	Myelodysplastic Syndrome	Chr del(5)(q31)	Myelodysplastic Syndrome	lenalidomide Sensitive: B - Late Trials lenalidomide Sensitive : B	lenalidomide Sensitive: B - Late Trials lenalidomide Sensitive : B
No biomarker	Myelodysplastic Syndrome	No biomarker	Myelodysplastic Syndrome	MBG453 Sensitive: B - Late Trials MBG453 Sensitive : B	MBG453 Sensitive: B - Late Trials MBG453 Sensitive : B
No biomarker	Myelodysplastic Syndrome	No biomarker	Myelodysplastic Syndrome	venetoclax Sensitive: B - Late Trials venetoclax Sensitive : B	venetoclax Sensitive: B - Late Trials venetoclax Sensitive : B
No biomarker	Myelodysplastic Syndrome	No biomarker	Myelodysplastic Syndrome	KPT-8602 Sensitive: B - Late Trials KPT-8602 Sensitive : B	KPT-8602 Sensitive: B - Late Trials KPT-8602 Sensitive : B

Myelodysplastic Syndrome

Associations(126)

Associations
(126)